Alvogen has been selected as the preferred bidder for acquisition of DreamPharma
Alvogen has been selected as the preferred bidder for acquisition of DreamPharma.
On July 4, according to the pharmaceutical industry, Hanwha Chemical and Citigroup Global Markets Securities selected Alvogen as the proffered bidder for acquisition of DreamPharma.
Alvogen is a global generic com...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
